Nikolina Icitovic.

Stephen P . Peters, M.D., Ph.D., Susan J. Kunselman, M.A., Nikolina Icitovic, M.A.S., Wendy C. Moore, M.D., Rodolfo Pascual, M.D., Expenses T. Ameredes, Ph.D., Homer A. Boushey, M.D., William J. Calhoun, M.D., Mario Castro, M.D., Reuben M. Cherniack, M.D., Timothy Craig, D.O., Loren Denlinger, M.D., Ph.D., Linda L. Engle, B.S., Emily A. DiMango, M.D., John V. Fahy, M.D., Elliot Israel, M.D., Nizar Jarjour, M.D., Shamsah D. Kazani, M.D., Monica Kraft, M.D., Stephen C. Lazarus, M.D., Robert F. Lemanske, Jr., M.D., Njira Lugogo, M.D., Richard J. Martin, M.D., Deborah A. Meyers, Ph.D., Joe Ramsdell, M.D., Christine A. Sorkness, Pharm.D., E. Rand Sutherland, M.D., Stanley J.

Significantly fewer patients in the anacetrapib group than in the placebo group experienced levels of liver enzymes which were greater than 3 times the upper limit of the standard range in consecutive measurements . Among patients with diabetes, there was no significant difference between your groupings in glycemic control; there was a development toward a lower glycated hemoglobin level with anacetrapib at 24 weeks and at 76 weeks . Clinical End Factors During the 76-week study-treatment stage, the prespecified, adjudicated composite cardiovascular end point occurred in 16 individuals in the anacetrapib group in comparison with 21 in the placebo group .